A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in
combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma
subjects